Department of Palliative Medicine, University Hospital Llandough, Penarth, UK.
Cardiff University, Cardiff, UK.
Eur J Cancer Care (Engl). 2019 May;28(3):e13004. doi: 10.1111/ecc.13004. Epub 2019 Feb 13.
Clinician-rated performance status (C-PS) is used routinely to predict whether patients are fit enough to undergo treatment for lung cancer. However, a good proportion of those with seemingly good C-PS do not go on to receive, let alone complete treatment. The value of C-PS in accurately predicting this is unclear, as is the merit of evaluating patient-rated PS (P-PS).
Our aim was to prospectively assess Eastern Cooperative Oncology Group (ECOG) and Karnofsky C-PS and P-PS in patients attending a rapid access lung cancer service (RALCS), the agreement between these scores, and whether any score could predict receipt and completion of multidisciplinary team (MDT)-planned treatment.
ECOG and Karnofsky scores were highly correlated (Spearman's rho -0.79 for C-PS and -0.828 for P-PS, both p < 0.001). There was poor agreement between C-PS and P-PS scores (kappa statistics 0.275 for ECOG and 0.172 for Karnofsky); however, clinicians did not tend to consistently under- or overestimate patients' scores. ECOG P-PS showed an association with completion of MDT-planned treatment (p = 0.007), but C-PS did not.
Clinician-rated PS was not associated with completion of MDT-planned treatment, but there may be a role for patient-rated PS. C-PS and P-PS were poorly correlated in a RALCS.
临床医生评估的体能状态(C-PS)常用于预测患者是否适合接受肺癌治疗。然而,相当一部分体能状态看似良好的患者并未接受治疗,更不用说完成治疗了。C-PS 在准确预测这一点上的价值尚不清楚,评估患者自评体能状态(P-PS)的价值也是如此。
我们的目的是前瞻性评估快速通道肺癌服务(RALCS)中患者的东部合作肿瘤学组(ECOG)和卡诺夫斯基 C-PS 和 P-PS,这些评分之间的一致性,以及任何评分是否可以预测多学科团队(MDT)计划治疗的接受和完成情况。
ECOG 和卡诺夫斯基评分高度相关(C-PS 的斯皮尔曼 rho 为-0.79,P-PS 的 rho 为-0.828,两者均 p<0.001)。C-PS 和 P-PS 评分之间的一致性较差(ECOG 的 Kappa 统计量为 0.275,卡诺夫斯基的 Kappa 统计量为 0.172);然而,临床医生并没有倾向于一致地低估或高估患者的评分。ECOG P-PS 与 MDT 计划治疗的完成相关(p=0.007),但 C-PS 则不然。
临床医生评估的 PS 与 MDT 计划治疗的完成无关,但患者自评 PS 可能有一定作用。在 RALCS 中,C-PS 和 P-PS 相关性较差。